Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bcg5.0
B. coagulans – Forschung
Überwiegend Mechanismus / Beobachtung
27 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu B. coagulans sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2009–2026 mit einer typischen Studiengröße von 40 Teilnehmenden.
Basierend auf 27 Studien · 2 Meta-Analysen · 20 RCTs · 1,164 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
IBS, abdominal pain & stool formMeaningful reduction in abdominal pain, bloating and stool frequency in diarrhoea-predominant IBS and functional bloating; no benefit established for constipation · 4-12 weeks
Überwiegend Mechanismus / Beobachtung11 Studien
Gas & bloating
Überwiegend Mechanismus / Beobachtung5 Studien
Gut microbiome & colonic survival
Überwiegend Mechanismus / Beobachtung5 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung5 Studien
Protein & amino-acid absorption
Überwiegend Mechanismus / Beobachtung3 Studien
Exercise recovery & muscle damage
Zu wenige bewertete Studien1 Studie
Children's acute diarrhoea
Zu wenige bewertete Studien1 Studie
Aktives Forschungsgebiet
18 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2023
200920172026
1Übersicht2024
Einfach gesagt: It also addresses how to assess strains that have recently been discovered to possess probiotic properties.
Liang J et al. · Frontiers in cellular and infection microbiology (2024)
Compared to commonly used probiotic lactic acid bacteria, H. coagulans can produce spores, which provide the species with high resistance to adverse conditions.
Even though they are transient residents of the gut, beneficial bacteria can have a significant impact on the microbiota because they can outnumber harmful germs, and vice versa.
This article discusses the probiotic mechanisms of H. coagulans and outlines the requirements for a substance to be classified as a probiotic.
Einfach gesagt: In this exploratory study, B coagulans MY01 and B subtilis MY02 were efficacious and safe in the treatment of functional dyspepsia.
Wauters L et al. · The lancet. Gastroenterology & hepatology (2021)
In this exploratory study, B coagulans MY01 and B subtilis MY02 were efficacious and safe in the treatment of functional dyspepsia.
Participants had potentially beneficial immune and microbial changes, which could provide insights into possible underlying mechanisms as future predictors or treatment targets.
Einfach gesagt: C butyricum and B coagulans may effectively inhibit H pylori to some extent, with rare adverse events, and thus may reduce the burden of antibiotic resistance.
Zhang J et al. · Medicine (2020)
The ITT analysis demonstrated that the 3 groups achieved similar eradication rates (18%, 20%, and 26%, respectively, P = .597).
The PP analysis yielded a similar result (24.3%, 26.3%, and 32.5%, respectively, P = .703).
The 3 groups had comparable compliance rates (74% vs 76% vs 80%, P > .05).
Einfach gesagt: Current evidence supports the use of BC01 as a therapeutic option for managing functional constipation.
Xu Y et al. · Medicine (2025)
After 21 days of treatment, the values of Bristol and Gastrointestinal Quality of Life Index were significantly increased by BC01 supplementation, and the Cleveland scores was decreased in patients with functional constipation.
Besides, the contents of acetic acid and isobutyric acid significantly increased by treated with BC01.
Current evidence supports the use of BC01 as a therapeutic option for managing functional constipation.
Einfach gesagt: Across 81 randomised trials, B. coagulans MTCC 5856 ranked at the very top for abdominal pain and for stool form in diarrhoea-predominant IBS.
Xie P et al. · Nutrients (2023)
B. coagulans MTCC 5856 (SUCRA 96.9%) and B. coagulans Unique IS2 (SUCRA 92.6%) were among the most effective probiotics for improving abdominal pain
B. coagulans MTCC 5856 ranked first for improving the Bristol stool form scale in IBS-D (SUCRA 99.6%)
9,253 participants from 81 RCTs, literature searched to June 2023
Einfach gesagt: A clean between-group result in functional gas and bloating — indigestion scores collapsed on the probiotic and barely moved on placebo.
Majeed M et al. · Medicine (Baltimore) (2023)
GSRS indigestion score fell from 8.91 to 3.06 in the probiotic group versus 9.42 to 8.43 on placebo; between-group P<0.001
Median global evaluation of patient's score improved from 3.0 to 9.0 versus 3.0 to 4.0 on placebo (P<0.001)
Cumulative GSRS score excluding indigestion fell 27.82% to 4.42% versus 29.12% to 19.33% (both P<0.001)
Einfach gesagt: Significantly increased absorption of BCAA with supplementation of B. coagulans Unique IS-2 along with whey protein and improvement in leg press and vertical jump power was noted indicating the positive effect of the probiotic on muscle power in the lower body.
Tarik M et al. · European journal of nutrition (2022)
A positive effect of probiotic Bacillus coagulans Unique IS-2 supplementation was observed on protein absorption as evidenced by an increase in total PFAA by + 16.1% (p = 0.004).
Branched chain amino acids (BCAA) comprising isoleucine (p = 0.016), leucine (p = 0.001), and valine (p = 0.002) were increased by + 33.1% in ITT analysis as compared to placebo after 60 days.
At 30 days an increase in isoleucine by + 35% (p = 0.113), leucine by + 43% (p = 0.032), and valine by + 32% (p = 0.017) was observed in ITT analysis.
Einfach gesagt: Future research should prioritize large-scale clinical trials, multi-omics mechanistic investigations, and the development of synbiotic formulations to fully realize its potential as a next-generation therapeutic agent.
Ke S et al. · Food & function (2026)
Notably, therapeutic effects are strain-specific: H. coagulans MTCC 5856 (2 × 1010 CFU day-1) significantly reduces abdominal distension (P < 0.01), while the strain Unique IS-2 alleviates anxiety-like behaviors by upregulating hippocampal BDNF.
The underlying mechanisms involve the production of short-chain fatty acids (SCFAs), modulation of the TLR4/MyD88/NF-κB signaling pathway, and suppression of oxidative stress.
Although toxicological assessments establish a no observed adverse effect level (NOAEL) of >1000 mg kg-1 in rodent models, its limited capacity for intestinal colonization presents a clinical challenge.
Einfach gesagt: Bariatric surgery (BS) produces positively impacting metabolic results in morbidly obese patients.
Kazzi F et al. · Alternative therapies in health and medicine (2021)
The LWG had a significant decrease in AST and LDL compared to the placebo group (P = .03).
Bariatric surgery (BS) produces positively impacting metabolic results in morbidly obese patients.
Our study shows that in the case of triglycerides, LDL, weight loss and AST, administering of a probiotic/prebiotic blend may play a role in improving clinical outcomes of morbidly obese patients undergoing LSG.
11Übersicht2026
Einfach gesagt: Large-scale randomized controlled trials are warranted to validate probiotic efficacy in Long COVID and reduce burden on individual health and healthcare institutions.
Khalid K et al. · Virology journal (2026)
Approximately 10% of infected experience autonomic dysfunction, cardiovascular complications, and neurological impairments.
In light of evidence supporting a strong association of Long COVID with gut dysbiosis, probiotics have emerged as a promising intervention.
Clinical studies have shown that Bacillus coagulans, Bacillus subtilis, Lactobacillus acidophilus, and Bifidobacterium species can improve fatigue, gastrointestinal health, and overall physical and mental well-being in Long COVID patients.
Einfach gesagt: Novel nosocomial infection prevention and control combined with intestinal probiotics could promote the therapeutic effect of the children, improve the immune function, and promote the quality of life of children with hand, foot and mouth disease.
Tao Y et al. · JPMA. The Journal of the Pakistan Medical Association (2025)
Of the 100 patients, 50(50%) were in Group 1; 25(50%) boys and 25(50%) girls with mean age 3.49±1.93 years.
There were 50(50%) patients in Group 2; 26(52%) boys and 24(48%) girls with mean age 3.52±2.03 years (p>0.05).
Compared to Group 1, patients in Group 2 had shorter time of symptom resolution, fever resolution, length of hospital stay, better total effective rate, lower frequency of adverse reactions and higher nursing satisfaction (p<0.05).
Einfach gesagt: The present study results suggest that LactoSpore is safe for consumption and does not alter the gut microbiome of healthy individuals.
Majeed M et al. · Medicine (2023)
The present study results suggest that LactoSpore is safe for consumption and does not alter the gut microbiome of healthy individuals.
Minor changes in a few bacterial species may have a beneficial outcome in healthy individuals.
The results reiterate the safety of B. coagulans microbial type culture collection 5856 as a dietary supplement and provide a rationale to explore its effect on gut microbiome composition in individuals with dysbiosis.
Einfach gesagt: This study provides important new data on how spore-forming B. coagulans SNZ 1969 contributes to improving gut motility and presents evidence supporting the use of B. coagulans SNZ 1969 in adults with mild intermittent constipation and habitual low intake of fruit and vegetables.
Kang S et al. · Food research international (Ottawa, Ont.) (2021)
BC supplementation significantly improved CTT (p = 0.031), CSBM at weeks 2 (p = 0.045) and 9 (p = 0.038), and BDS at weeks 3 (p = 0.019) and 6 (p = 0.029) compared with the placebo, while altering the community composition of the gut microbiota.
We also confirmed that BC was effectively delivered to the gut.
Finally, the multivariate redundancy analysis concluded that BC-induced enrichment of Lactobacillales and diminishment of Synergistales were related to CTT improvements.
Einfach gesagt: B coagulans LBSC was safe for human consumption and efficacious in alleviating overall pathophysiological symptoms of IBS and thereby improving inclusive quality of life evaluated.
Gupta AK et al. · Medicine (2021)
Assessment through Digestive Symptom Frequency Questionnaire 5 point Likert scale showed significant improvement in interventional arm compared to placebo on symptoms such as bloating/cramping, abdominal pain, diarrhea, constipation, stomach rumbling, nausea, vomiting, headache, and anxiety.
B coagulans LBSC was safe for human consumption and efficacious in alleviating overall pathophysiological symptoms of IBS and thereby improving inclusive quality of life evaluated.
Einfach gesagt: A difference was observed in the Firmicutes/Bacteroidetes ratio between the constipation-dominant group (118.0) and diarrhea-dominant group (319.2), but this difference was not significant.PROBACI provided control of abdominal pain, less discomfort during defecation, and a more normalized defecation style, especially in the constipation-dominant group.
Chang CW et al. · Medicine (2020)
Compared with the diarrhea group, the constipation group achieved greater improvements in terms of discomfort during defecation (2.5 ± 0.7 to 3.1 ± 0.7, P = .02) and normalization of defecation style (50% vs 7.1%, P = .007) by day 28.
The defecation characteristics, discomfort level, and effort required for defecation were recorded.
Venkataraman R et al. · Probiotics and antimicrobial proteins (2023)
The significant reduction of sensation of incomplete evacuation, defecation-, and abdominal-pain correlated with the strains ability to produce short-chain fatty acids.
Overall, results indicated that B. coagulans Unique IS2 addition to lactulose reduced time required to relieve constipation as compared to lactulose alone.
In conclusion, B. coagulans Unique IS2 with lactulose is more effective than lactulose alone to relieve symptoms of constipation in a shorter period.
Einfach gesagt: No significant change in interleukin-6 levels was observed; however, the safety assessment revealed an excellent profile with no reported severe adverse events.
Shaikh SS et al. · Medicine (2024)
B. coagulans BCP92 significantly improved IBS severity (P < .001), and gastrointestinal symptom frequency (P < .001) compared with that in the control group.
The stool consistency significantly improved (P < .001).
Einfach gesagt: A real microbiota shift in older adults, and — contrary to how it is usually cited — no immune effect between treatments.
Nyangale EP et al. · J Nutr (2015)
Faecalibacterium prausnitzii increased by 0.1 log10 cells/mL more than on placebo (P=0.03); Bacillus spp. rose 0.5 log10 from baseline (P=0.007)
IL-10 from LPS-stimulated PBMCs rose 0.2 ng/mL from baseline after 28 days (P<0.05), but NO overall difference was found in the effect of the treatments — the between-treatment immune comparison was null
No effect reported on natural killer cell activity or C-reactive protein